Danish Multiple Sclerosis Center, Department of Neurology 2082, Rigshospitalet and University of Copenhagen, 2100, Copenhagen, Denmark.
CNS Drugs. 2017 May;31(5):357-371. doi: 10.1007/s40263-017-0414-3.
Treatment of multiple sclerosis (MS) has improved considerably over the last decade because of new insights into MS pathology and biotechnological advances. This has led to the development of new potent pharmaceutical compounds targeting different processes in the complex autoimmune pathology leading to chronic central nervous system (CNS) demyelination, neural loss, and, finally, neurological disability. Although a number of disease-modifying treatments are available for the treatment of the inflammatory phase of MS, there is still a need for highly efficacious therapies with an acceptable safety profile in order to gain therapeutic control early in the disease course. Monoclonal antibodies have proven to be some of the most efficacious disease-modifying therapies in the field of MS, and recent developments in clinical research hold promise for new compounds fulfilling the need for improved safety and high efficacy. We review recent developments in the field of therapeutic monoclonal antibodies used for the treatment of MS and current information on the mode of action, efficacy, and safety of existing and emerging therapeutic monoclonal antibodies as well as their place within the context of different treatment strategies. Finally, we consider the most important future developments.
过去十年中，由于对多发性硬化症（MS）病理学的新认识和生物技术的进步，MS 的治疗得到了极大改善。这导致了针对导致慢性中枢神经系统（CNS）脱髓鞘、神经丢失最终导致神经功能障碍的复杂自身免疫病理学中不同过程的新型有效药物化合物的发展。尽管有许多疾病修饰疗法可用于治疗 MS 的炎症阶段，但仍需要具有可接受安全性特征的高效疗法，以便在疾病过程的早期获得治疗控制。单克隆抗体已被证明是 MS 领域最有效的疾病修饰疗法之一，临床研究的最新进展为满足提高安全性和高效性需求的新型化合物带来了希望。我们回顾了用于治疗 MS 的治疗性单克隆抗体领域的最新进展，以及现有和新兴治疗性单克隆抗体的作用机制、疗效和安全性方面的最新信息，以及它们在不同治疗策略中的地位。最后，我们考虑了最重要的未来发展。
